Suzanne Jadico, MD
Ophthalmology · Princeton, NJNPI 1376744342
Payments from drug & device makers
Across 109 payments — averaging $32.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Sight Sciences, Inc.$374
- AbbVie$367
- Bausch & Lomb, A Division Of Bausch Health US, LLC$155
- Novartis$142
- Bausch & Lomb Americas Inc.$124
- plus $843 from 13 others
What the payments were for
- Food & beverage$3,512100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 33 | $1,507 |
| Sight Sciences, Inc. | 5 | $374 |
| AbbVie(2 entities) | 13 | $367 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $155 |
| Novartis | 10 | $142 |
| Bausch & Lomb Americas Inc. | 8 | $124 |
| Dompe US, Inc. | 1 | $119 |
| Astellas Pharma US Inc | 1 | $117 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $115 |
| NEW World Medical,inc. | 1 | $110 |
| Sun Pharmaceutical Industries Inc. | 5 | $75 |
| Ocular Therapeutix, Inc. | 3 | $72 |
| Tarsus Pharmaceuticals, Inc. | 4 | $69 |
| Eyepoint US, Inc. | 4 | $61 |
| Biotissue Holdings Inc. | 2 | $32 |
| Harrow Eye, LLC | 2 | $29 |
| Shire North American Group Inc | 1 | $15 |
| Kala Pharmaceuticals, Inc. | 1 | $14 |
| Oyster Point Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$677
- Centurion$262
- OMNI(R) SURGICAL SYSTEM (US)$236
- XEN GLAUCOMA TREATMENT SYSTEM$137
- Oxervate$119
- Izervay$117
How this compares
$3,512 in reported general payments places this provider in the 70th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 61 | $98,454 |
| XiidraLifitegrast | 29 | $56,429 |
| MieboPerfluorohexyloctane/Pf | 28 | $30,672 |
| LumiganBimatoprost | 43 | $24,836 |
| CequaCyclosporine | 18 | $18,300 |
| ProlensaBromfenac Sodium | 45 | $15,468 |
| Cyclosporine | 17 | $15,032 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $9,818 |
| Travatan ZTravoprost | 23 | $8,423 |
| TyrvayaVarenicline Tartrate | 11 | $8,317 |
| RocklatanNetarsudil Mesylat/Latanoprost | 11 | $6,874 |
| Travoprost | 26 | $6,312 |
| Bromfenac Sodium | 22 | $5,524 |
| Prednisolone Acetate | 68 | $3,132 |
| Timolol Maleate | 57 | $3,056 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $367 | $133,109116 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $124 | $87,10057 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $155 | $18,51269 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $75 | $18,30018 claims |
| NovartisTravatan Z | $142 | $8,42323 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $13 | $8,31711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Princeton
- Rahul TonkPrinceton$70K
- Daniel LeePrinceton$68K
- Patrick HigginsBloomfield$16.7M
- Jai ParekhWoodland Park$2.1M
- Eric MannDover$860K
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Luis Gonzalez GonzalezTeaneck$727K
- Cynthia MatossianPennington$726K
- Charles CraneSouth Orange$582K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.